ערך בספרים למניה: Ascendis Pharma AS (ASND)

Scaling the portfolio of Ascendis Pharma A/S (ASND) appears risky, yet the projected book value per share confirms asset stability. The parameter value stands at 24.88, proving the effective monetization of its unique drug delivery system. The biotech's revenues are based on insurance fund payments for the treatment of rare endocrine pathologies, ensuring steady capital growth for the issuer.

Professional capital evaluates the issuer through the prism of the real value of its net assets. This indicator is calculated as the difference between total equity and liabilities, divided by the number of shares. By analyzing the trend in book value per share, an investor sees the actual volume of equity. For Ascendis Pharma A/S (ASND), this reflects the efficiency of investments in prolonged therapies. Steady growth in this metric confirms financial stability prior to scaling production.